IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.

Revenue
+9.86%
EPS
+17.3%
Free cash flow
+17.6%
Total debt
−28.6%

Quarter to September 2026, against a year earlier

677.29 6.58 +0.98%
Market cap
$52.8B
P/E
44.8×
Fwd P/E
37.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
9 9 8 8

+8 more TTM periods

ROE
68.93% 74.21% 72.92% 66.20%
ROA
33.33% 33.65% 33.19% 31.89%
ROIC
46.00% 48.87% 48.68% 45.33%
Return on Tangible Assets
122.14% 119.33% 122.43% 104.65%
Average Days of Receivables
48.21 50.27 49.55 46.85
Free Cash Flow per Share
16.49 15.67 13.28 11.89
Free Cash Flow
1,300.00 1,237.09 1,058.11 956.58
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026